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Summary
Aim: This study aimed to summarise our recent clini-
cal experience with children and adolescents selected
for heart transplantation with a focus onmorbidity and
mortality during the waiting time.
Methods: This was a single centre, retrospective
study of all consecutive patients listed for heart trans-
plantation between 1994 and 2008 who were less than
20 years old. Clinical parameters, ECG, echocardio-
graphy and catheter data as well as duration and com-
plications of mechanical circulatory support, were
reviewed from the date of listing to the date of trans-
plantation or death.
Results: The study population consisted of 20 pa-
tients with a median age at the time of listing of 13.8
years (range 1–19.6 years). Cardiomyopathy was pre-
sent in 17 patients (dilated 11, restrictive 3, hyper-
trophic 1 and unclassified 2) and a congenital heart de-
fect was present in 3. In 13/20 patients, a significant
arrhythmia was noted: ventricular fibrillation 2, non
sustained ventricular tachycardia 6, supraventricular
tachycardia 8 and complete atrioventricular block
4 events. A total of five patients died whilst on the
waiting list. The median time to transplantation or
death was 61 days (range 1–318 days). The estimated
survival rate (Kaplan Meier) was 88, 71 and 47% at 1,
3 and 5 months respectively. There was no difference
between the patients who died on the waiting list and
the patients who survived to transplantation regarding
age, sex, heart failure, arrhythmia and echocardio-
graphic findings. Patients with dilated cardiomyopa-
thy were overrepresented in the group who survived to
transplantation (13/15 versus 1/5, p 0.014). Mechanical
circulatory support was used in 13/20 patients for a
median duration of 59 days (range 1–361 days) result-
ing in 18 events of complications: thrombosis or embo-
lia 6, bleeding 9, and significant in-
fection or sepsis 3 events. In one
patient, a clinically relevant hemi-
sydrome persisted.
Conclusion: The survival to
transplantation rate was accepta-
ble in our cohort and is similar to
other studies. There were relatively few deaths in pa-
tients with dilated cardiomyopathy. Otherwise, an ad-
verse outcome cannot be predicted from clinical or
haemodynamic data at the time of listing for trans-
plantation. Thrombo-embolic events continue to be a
major issue in patients with mechanical circulatory
support.
Key words: paediatric heart transplantation; con-
genital heart disease; ventricular assist device; heart
failure
Introduction
Paediatric heart transplantation has been per-
formed since 1982 [1]. In the past 28 years, the practice
of paediatric cardiac surgery has evolved dramatically
and heart transplantation is now available as an at-
tractive treatment option for children and adolescents
with end-stage heart failure. The actual estimated
transplant half life (the time at which 50% of recipients
remain alive) is now better than the average half life in
adults and ranges from 11.3 to 15.8 years with the best
survival reported in infants [1–3].
One of the main issues in paediatric heart trans-
plantation is the lack of appropriate donor organs [4].
During the waiting time, the patients are at an in-
creased risk for a further deterioration of the heart,
and for the occurrence of arrhythmia or infection. Some
patients may need mechanical circulatory support as a
relatively safe “bridge” to transplantation. Children
listed for heart transplantation face the highest wait-
ing list mortality out of all solid-organ transplant pa-
tients [5].
The aim of this study was to critically assess our
current approach to paediatric patients with end-stage
heart failure who were identified as candidates for
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cialised psychiatrist. A stable psychosocial background
and evidence of strong motivation of the patient and
the family were required. Donor and recipient were
matched for ABO blood-type compatibility and body
weight. A donor heart was obtained from a beating-
heart brain dead individual through cooperation with
the Swiss Transplant Organisation.
The routine diagnostic workup before heart trans-
plantation included transthoracic echocardiography
and right heart catheterisation, if possible. Due to the
retrospective design of the study, the catheter datasets
were incomplete and therefore they were not included
in this paper. Pulmonary artery pressure was esti-
mated echocardiographically by measurement of the
pressure gradient between the right atrium and the
right ventricle from the regurgitation of the tricuspid
valve, and was graded relative to the simultaneously
measured systolic blood pressure as mild (below half
systemic pressure), moderate (equal or higher than
half systemic pressure but below two thirds of the sys-
temic pressure) or severe (equal or higher than two
thirds of the systemic pressure).
Patients who survived the waiting time (“group
survive”) were compared with patients who died while
waiting for heart transplantation (“group death”), to
analyse for potential risk factors.
The study was approved by the local hospital ethi-
cal committee, and written informed consent was ob-
tained for the data collection.
Statistics
Measurements are given as median and range. Patient
groups were compared using the Mann-Whitney-test
and Fishers-Exact-test. A significant difference was
defined as p value <0.05. Patient survival was calcu-
lated on the basis of the Kaplan Meier survival analy-
sis. Echocardiographic measurements were compared
using the Z score. For statistical analysis, we used
SPSS version 14.0 for Windows.
Results
A total number of 20 patients younger than 20 years
were listed at our institution during the study period of
15 years. There were 8 female and 12 male patients,
and the median age at the time of listing for transplan-
tation was 13.8 years (range 1–19.6). There was an
asymmetric age distribution with only 4 patients aged
10 years or less (fig.1). The volume of cases per year
varied from 0 to 3 patients. The median weight was
41 kg (range 10–94). Most but not all patients had se-
vere symptoms of heart failure at the time of listing
(NYHA 4: n = 13; NYHA 3: n = 5; NYHA 2: n = 2 [7]).
The blood type of the listed patients was 0 in 7 patients,
A in 9, B in 3 and AB in 1 patient.
Cardiomyopathy was the reason for heart failure
in most of the patients (17/20; dilated 11, restrictive 3,
heart transplantation, and to compare the morbidity
during the waiting time until the time of transplanta-
tion or death, within the last years at our centre.
Methods
This was a retrospective study in a single tertiary care
centre. All consecutive patients of less than 20 years of
age who were listed for heart transplantation for any
reason, between the years 1994 to 2008 were included
in the study. Data were collected retrospectively from
patient charts and nursing notes. Echocardiography
measurements were retrieved from our electronic data-
base.
For data collection, we focused on the waiting time,
which was the time between the listing for transplan-
tation until the time of removal from the waiting list
due to transplantation, death or recovery. The pre-
transplant clinical condition and assessment as well as
the early post transplant mortality were also included
in the study. A special emphasis was put on patients
with mechanical circulatory support regarding mode,
duration and rate of complication.
Patients with cardiomyopathy were divided into
five groups: dilated, hypertrophic, restrictive, right
ventricular arrhythmogenic and unclassified cardio-
myopathies (such as non-compaction), in accordance
with the report of the WHO/ISFC task force [6].
The indication for a heart transplant was individu-
ally judged using a multidisciplinary team approach.
The following general rules were applied: candidates
for heart transplantation were patients with end-stage
heart failure with an estimated life expectancy of less
than six months from any aetiology without any other
feasible medical or surgical treatment option, in the
absence of a systemic disease, infection, stroke or re-
cent pulmonary infarction. During the study period, it
was our policy not to perform heart transplantations
within the first year of life. The psychosocial back-
ground of patients was routinely evaluated by a spe-
Figure 1
Age distribution at the time of listing for heart transplantation.
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to hospital discharge rate of 62% (8/13) for all patients
with mechanical circulatory support. The median du-
ration of ventricular assist device in this cohort of 13
patients was 59 days, with a range of 1–361 days. Var-
ious types of assist devices were used: pulsatile sys-
tems were used in 7 patients (Berlin Heart Excor 6,
Abiomed 1) and non-pulsatile systems in 6 patients
(DeBakey 5, Biomedicus 1). One patient had to be sup-
ported with extracorporal membrane oxygenation
(ECMO) in addition to the implanted assist device for
20 days. The Berlin Heart Excor was the preferred de-
vice in the most recent patients. The total cumulative
number of days on mechanical circulatory support was
1018. Events of all 13 patients who underwent me-
chanical circulatory support are listed in table 1. The
major complications were 3 thrombo-embolic neu-
rologic events in 2 patients, leading to a clinically
relevant hemi syndrome in one patient. There was no
instance of technical failure of the blood pump com-
ponents or of the driving systems.
Clinical course during waiting time
The median time of waiting was 61 days (range 1–318
days). A total of 14 patients finally underwent heart
transplantation, 5 patients died whilst on the list
(table 2) and 1 patient with dilated cardiomyopathy
(DCM) recovered on the assist device and was dis-
charged home on oral medication. The in-hospital sur-
vival rate of the whole study population of 20 patients
hypertrophic 1 and unclassified 2). The aetiology of the
dilated cardiomyopathy was as follows: myocarditis (5),
muscular dystrophia (2), mitochondrial disease (1), an-
thracycline induced (1) and unknown (2). In 2 patients
with dilated cardiomyopathy and myocarditis, Parvo-
virus B19 and Enterovirus were found in the endomyo-
cardial biopsy as a possible aetiology in 1 patient each.
Two patients had an unclassified cardiomyopathy, and
their ventricular myocardium showed the typical as-
pect of a left ventricular non-compaction. Structural
heart disease was seen in 3 patients, with 2 patients
having a single ventricle. Both patients had left atrial
isomerism and a severe stenosis of the pulmonary
valve, palliated with systemic to pulmonary artery
shunts. The third patient was postoperative atrial
switch (Senning) for D-Transposition with intact ven-
tricular septum and additional myocardial ischemia
due to a thrombo-embolic obstruction of the right coro-
nary artery.
Mechanical circulatory support was initiated in
13/20 patients (65%) because of a rapidly worsening
clinical condition. A total of 10 patients were success-
fully bridged to transplantation, leading to a survival
Table 1
Description of technical data and events in patients with mechanical
circulatory support (MCS); cumulative support time was 1018 days.
Number of patients
Total n = 13
Mode of MCS
Biventricular
Left ventricular only
Right ventricular only
2
10
1
Complications during MCS
Infection/Sepsis
Bleeding
Thrombosis/Embolia*
3
9
6
Reoperations during MCS
Revision for significant bleeding
Cannula exchange
Chamber exchange
Cannula replacement
8
1
1
1
*3 cerebral thrombo-embolic events in two patients, resulting
in a clinically relevant hemi syndrome in one patient
Table 2
Characteristics of patients who died during the waiting time (5/20).
Diagnosis MCS Cause of death Time on waiting list (days)
Patient 1 RCM No Progressive atrial arrhythmia 76
Patient 2 HOCM Yes Sepsis 138
Patient 3 Single ventricle Yes Ventricular fibrillation 8
Patient 4 RCM Yes Progressive atrial arrhythmia 61
Patient 5 DCM No Ventricular fibrillation 15
Figure 2
Freedom from death while waiting.
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in five patients (moderate 3/13 and severe 2/13). Of the
two patients with a single ventricle, there was no rele-
vant atrioventricular valve regurgitation.
All patients underwent repeated psychiatric
counselling. One patient had suicidal ideation and an-
other one had episodes of oppositional attitude. Contin-
uous oral psychotropic medication was applied in 8/18
patients. The general qualitative psychological condi-
tion was good in 9 patients, mildly impaired in 5 and
severely impaired in 4 patients. In two patients this
data was not available.
was therefore 75% (15/20) (fig. 2). A total of three
patients died early after heart transplantation from
sepsis (2) and graft failure (1), resulting in a survival
rate to hospital discharge of 60% (12/20). Demographic
and clinical data was compared between the group of
patients who died while waiting for an appropriate do-
nor heart and the group who survived to transplanta-
tion (table 3).
Mechanical ventilation for progressive heart fail-
ure was necessary in 8/20 patients at the time of list-
ing, and one patient could be weaned from the respira-
tor during the waiting time. Arrhythmia was noted in
13/20 patients (65%; table 4). Ventricular fibrillation
was observed in 2/20 patients. Every patient who died
was affected by heart rhythm disturbances. None of
the patients underwent preventative implantation of a
cardioverter-defibrillator (ICD).
Echocardiography showed a decreased ventricular
function in 19/20 patients. Median ejection fraction in
patients with DCM was 20% (range 5 to 40%). Moder-
ate or severe mitral valve regurgitation was seen in
4/11 and moderate or severe pulmonary hypertension
in all 11 patients. The ejection fraction of the three
patients with restricted cardiomyopathy (RCM) was a
median of 46% (40–63%) at the time of indication and
40% (32–63%) at the time of transplantation. The pa-
tient with hypertrophic cardiomyopathy (HCM) had an
ejection fraction of 46%. Pulmonary artery hyperten-
sion was noted in 17/20 patients. It was assessed by
echocardiography estimation as mild in 4/20, moderate
in 12/20 and severe in 1/20. A relevant mitral valve re-
gurgitation in patients with two ventricles was present
Table 3
Patient characteristics; comparison of patients who died on the waiting list with patients who survived to transplantation (ns: p >0.05).
Died while waiting Survived to HTPL p
Number of patients (n) 5 15
Age (years); median (range) 7.3 (1.8–17.7) 12.1(1–19.6) ns
Sex: female/male 2/3 6/9 ns
Waiting time (days); median (range) 61 (8–138) 61 (1–318) ns
Dilated cardiomyopathy (n) 1 13 0.014
Congenital heart defect 1 1 ns
NYHA Class 4 (n) 2 11 ns
Ventricular function
EF (median)
46 20 ns
Atrioventricular valve regurgitation moderate or severe (n) 2 10 ns
Aortic valve regurgitation moderate or severe (n) 0 1 ns
Inotropic support at time of listing 2 10 ns
Mechanical ventilation at time of listing 3 5 ns
Pulmonary hypertension moderate or severe (n) 3 10 ns
Mechanical circulatory support 3 10 ns
ECMO 1 1 ns
Arrhythmia 5 8 ns
Table 4
Arrhythmia observed on 24 h Holter monitoring at the evaluation
for transplantation or during waiting time (n=20; multiple answers
possible).
n
No arrhythmia 7
Supraventricular tachycardia
Atrial flutter 2
Atrial fibrillation 5
Non sustained AV reentrant tachycardia 1
Ventricular arrhythmia
Frequent isolated premature ventricular complexes 3
Non sustained ventricular tachycardia 6
Ventricular fibrillation 2
Bradycardia
Sinus node dysfunction 2
Complete heart block 4
Pacemaker for bradycardia 4
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current era. In 2007, a new lawwas introduced in Swit-
zerland with the aim to improve the process of the al-
location of donor organs and a new allocation system
has been introduced which may shorten the waiting
time substantially in the future [18]. In children, the
coordination and allocation of donor organs also im-
proved in 2009 due to the European Children Heart
list, in which all members of the European Organ Ex-
change Organisation are able to list their patients un-
der the age of twelve years.
Regarding waiting list mortality, dilatative cardio-
myopathy was more common within the survivors of
our cohort (table 4). This observation has been con-
firmed in other series with the exception of patients on
ECMO, on mechanical ventilation or with severe ar-
rhythmias [19].
In our series, a relative high number of patients re-
quired mechanical circulatory support (MCS) (13/20 =
65%) when compared to another recently published se-
ries with the use of MCS in only 13% of the patients
[20]. This may be due to a relatively generous indica-
tion of MCSmainly in the early years of our study. The
technical progress of MCS within the last years has
opened up this treatment option for the paediatric age
group and even for infants [21]. However, it is still as-
sociated with a relevant morbidity and mortality. To
minimise technical errors and because of the favoura-
ble experience in the paediatric age group [22], in the
recent era we concentrated on one single pulsatile sys-
tem. In MCS patients we were able to reach an accept-
able survival to hospital discharge rate of 62%. MCS
has been used in other centres with similar success
rates [23, 24]. Thrombo-embolic complications with
neurologic sequelae were the most common relevant
long term problems and continue to be a major issue.
These complications are well known and occur in 6 to
32% of the patients in recently published series [15, 16,
25].
Conclusion
Our current approach to children and adolescents with
end-stage heart failure is in line with other centres. Ar-
rhythmia was a common finding in our population. The
overall morbidity and mortality during the waiting
time was acceptable. A relatively high number of pa-
tients needed MCS. This did not result in an increased
waiting list mortality however. MCS is feasible in this
age group but should only be used in well selected pa-
tients because of the additional risk of complications
such as thrombo-embolia.
Limitations of the study
The power of this analysis is limited due to the retro-
spective study design and the relatively small number
of patients. The comparison of our findings with pub-
lished data from other centres is hindered because of a
Discussion
This paper gives a summary of our clinical experience
with paediatric and adolescent candidates for heart
transplantation within the last 15 years. Compared to
other centres, the age distribution and underlying
heart diseases of patients on the waiting list for heart
tranplantation were similar to our study population
[8, 9], whereas other centres, mainly from the United
States, have a higher rate of transplantations in in-
fants and younger children and also perform trans-
plantations for relatively more patients with congeni-
tal heart defects [5, 10]. This discrepancy may be
explained by our policy against infant heart transplan-
tation and by our belief in reconstructive surgery for
as long as possible in most end-stage heart failure
patients, shifting the time of the operation towards
teenagers and towards the group of patients with
cardiomyopathies. Also, we did not offer heart trans-
plantation to neonates with hypoplastic left heart syn-
dromes or one of its variants, while other centres rou-
tinely performed heart transplantations in this patient
group during this time period. Typically for the paedi-
atric age group, ischemic heart disease is much rarer
than in the adult cohorts and rare diseases such as re-
strictive cardiomyopathy or myocardial non compac-
tion are overrepresented in this cohort. The most fre-
quent type of cardiomyopathy in the current and other
series was dilated cardiomyopathy [9, 11, 12].
Arrhythmia was a common finding among our
study population (see table 5). In reviewing the individ-
ual cases, ventricular arrhythmia was seen in patients
with advanced myocardial damage whereas patients
with a predominant restrictive haemodynamic and di-
lated atria were seen to have supraventricular tachy-
cardia.
The individual decision regarding the timing of
heart transplantation is difficult in all patients but
even more so in children and adolescents. In this age
group, patients seem to cope well and for a relatively
long time, if the progression of the disease is slow.
Therefore it is difficult to predict further deterioration.
Together with the constant lack of donor organs, we
were relatively restrictive in listing a patient for heart
transplantation. The fact that the survival to trans-
plantation rate at our centre (75%) was similar to that
of other centres (67–82%) [3, 5, 12, 13] and that mor-
bidity and mortality rates were comparable [3, 14, 15],
indicates a similar state of the progress of the disease
at the time of listing and hence similar listing criteria
in other centres. This encourages us to continue with
our current approach in children and adolescents with
end stage heart failure.
The waiting time in other centres has been re-
ported to range from a median duration of 7 days to 5
months [3, 12, 16, 17]. According to the current data,
we calculated a median waiting time of 61 days in the
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possible selection bias regarding patients’ age, under-
lying diagnosis and listing criteria.
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